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Abstract RCAS1 is involved in generating the suppressive
profile of the tumor microenvironment that helps cancer
cells evade immune surveillance. The status of the cells
surrounding the cancer nest may affect both the progression
of the cancer and the development of metastases. In cases
of ovarian cancer, a large number of patients do not respond
to the applied therapy. The patient’s response to the applied
therapy is directly linked to the status of the tumor
microenvironment and the intensity of its suppressive
profile. We analyzed the immunoreactivity of RCAS1 on
the cells present in the ovarian cancer microenvironment in
patients with the disease; these cells included macrophages
and carcinoma-associated fibroblasts. Later we analyzed the
immunoreactivity levels within these cells, taking into
consideration the clinical stage of the cancer and the
therapeutic strategy applied, such as the number of
chemotherapy regiments, primary cytoreductive surgery, or
the presence of advanced ascites. In the patients who did
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DOI 10.1007/s00441-011-1216-4not respond to the therapy we observed significantly higher
immunoreactivity levels of RCAS1 within the cancer nest
than in those patients who did respond; moreover, in the
non-responsive patients we found RCAS1 within both
macrophages and carcinoma-associated fibroblasts. RCAS1
staining may provide information about the intensity of the
immuno-suppressive microenvironment profile found in
cases of ovarian cancer and its intensity may directly relate
to the clinical outcome of the disease.
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Introduction
Cancer cells must evade immune surveillance. Many
molecular mechanisms present within both the cancer
milieu and the cancer microenvironment participate in this
process of evasion. RCAS1 is a well-known membrane
protein that was discovered in 1996 by Sonoda (1996).
More specifically, it is a membrane II protein that is
expressed on various types of cancer cells, including those
of ovarian cancer. The presence of RCAS1 expression
correlates with a poor prognosis (Akahira et al. 2004;
Sonoda et al. 2008; Enjoji et al. 2005) for the case. This is
because this protein is able to suppress cytotoxic T
lymphocytes (CTLs) and NK cells (Nakashima et al.
1999; Y oshida et al. 2008) and it may evoke apoptosis of
these mononuclear immune cells as well as trough
activation of FADD in its cytoplasm (Matsushima et al.
2001). Some recent research papers have revealed that
RCAS1 expression is not limited to the cancer milieu but
can also be detected within cells derived from the cancer
microenvironment, such as macrophages or stromal cells
(Adamek et al. 2009; Dutsch-Wicherek 2010; Dutsch-
Wicherek et al. 2009; Enjoji et al. 2006). Moreover, the
presence of RCAS1 within the cancer microenvironment
seems to be related to the escape of the cancer cells from
immune surveillance (Sonoda et al. 1996; 2005a; b;
Giaginis et al. 2008; Enjoji et al. 2004a). In a similar way,
the function of RCAS1 is related to the soluble form of
RCAS1 (Sonoda et al. 1996; Giaginis et al. 2008; Enjoji et
al. 2004a; b; Dutsch-Wicherek and Wicherek 2008; Sonoda
et al. 2010). The soluble form of RCAS1, or sRCAS1, has
been detected in the blood sera of patients with various
types of carcinomas and, moreover, the level of sRCAS1
correlated inversely with the response to applied anti-cancer
therapy (Dutsch-Wicherek and Wicherek 2008; Sonoda et
al. 2006). It is well known that the status of the tumor
microenvironment is crucial for the development of the
cancer nest. Both stromal cells and even immune cells
present within the tumor microenvironment may help the
cancer to progress. The macrophages from the tumor
microenvironment, called tumor-associated macrophages
(TAM), may suppress the activity of cytotoxic immune
cells. Most likely, this process is realized by the expression
of various proteins present on the cell membrane of the
macrophages, including B7H4 and RCAS1 (Adamek et al.
2009; Dutsch-Wicherek 2010; Dutsch-Wicherek et al. 2009;
Kryczek et al. 2007; Kryczek et al. 2006). As immune cells
are able to suppress the activity of CTLs and NK cells,
RCAS1-positive macrophages probably participate in gen-
erating the suppressive profile of the tumor microenviron-
ment (Yoshida et al. 2008). The cellular profile of the tumor
microenvironment is important for the clinical outcome of
the cancer patient treatment. Not only do the macrophages
surrounding the tumor affect its homeostasis but recently
carcinoma-associated fibroblasts (CAFs) have been identi-
fied as a cellular population important for tumor growth.
Furthermore, tumor growth does not proceed uniformly
(Wu et al. 2011; Dutsch-Wicherek et al. 2010; Dutsch-
Wicherek et al. 2011). Consequently, in advanced carcino-
ma it is possible to distinguish different zones within the
tumor. For instance, one part of the tumor may be typified
by strongly matched proliferation while another zone may
be typified by apoptosis, necrosis, or hyalinization of the
stroma. The development of metastases is linked with
changes not only within the same tumor (e.g., the grading
of cancer cells) but also in the cancer microenvironment
itself. Most likely, the zones of the microenvironment
associated with strong tumor growth (highly matched
proliferation) differ from those zones in which there is
highly marked hyalinization of the stroma. For this reason
we decided to focus on RCAS1 immunoreactivity levels in
the different parts of the tumor as well as in the different
parts of its microenvironment. Since RCAS1 has been
identified as a protein involved in the regulation of
cytotoxic immune cells within the tumor microenvironment
in patients with ovarian and cervical cancer, we selected
RCAS1 for a planned immunohistochemical analysis that
would examine the different zones in both the cancer milieu
and in the cancer microenvironment.
In his study, Sonoda demonstrated that, while on the one
hand, the intensity of the RCAS1 immunoreactivity in
ovarian cancer cells was related to a poor prognosis for the
case (Sonoda et al. 2009), on the other hand, the presence
of RCAS1 expression within the cervical cancer microen-
vironment was associated with the potential to develop
metastases (Sonoda et al. 2005a; 2007). The participation of
RCAS1 in the development of metastases was also found in
other types of adenocarcinoma (Dutsch-Wicherek et al.
2009; Iwasaki et al. 2000; Nakabayashi et al. 2007).
Recently, RCAS1 has been proposed as a clinically useful
406 Cell Tissue Res (2011) 345:405–414marker for detecting various kinds of adenocarcinoma (Ali-
Fehmi et al. 2010; Giaginis et al. 2009). We therefore
decided to analyze the RCAS1 immunoreactivity levels
precisely, measuring them in a large group of patients
treated for ovarian cancer with both surgery and subsequent
chemotherapy. We detected the same kind of RCAS1
immunoreactivity profile within both the cancer milieu
and the cancer microenvironment. The differences in
RCAS1 immunoreactivity were analyzed according to
different clinical parameters, including the kind of surgery
performed and the response to the chemotherapy applied.
Methods
Patients
The patients included in the study were treated surgically
for ovarian cancer between December 2006 and January
2010 in the Department of Gynecology and Oncology of
the Lukaszczyk Oncological Center, Bydgoszcz, Poland.
All of the 74 patients involved underwent optimal cytor-
eductive surgery either during the primary surgical proce-
dure or following neoadjuvant chemotherapy. The
histological characteristics of the tumors are able presented
in Table 1: grading, histological type and FIGO stage
(Table 1). The patients were divided according to the
therapeutic strategy applied: These data are also presented
in Table 1 (Table 1). The patients included in our study were
observed after the surgical procedure and chemotherapy in
the Out-patient Unit of the Lukaszczyk Oncological Center,
Bydgoszcz, Poland. The period of the follow up observa-
tion was from 1 to 5 years.
The patient’s consent was obtained in each case. Prior to
the present study we also obtained the approval of the
Jagiellonian University Ethical Committee for our research
program (DK/KB/CM/0031/447/2010).
Immunohistochemistry
The RCAS1 immunoreactivity levels were evaluated in
samples obtained from 74 patients with primary ovarian
cancer treated at the Lukaszczyk Oncology Center,
Bydgoszcz, Poland. Formalin-fixed paraffin embedded
4 μm sections were de-waxed, hydrated gradually and
incubated with an anti-RCAS1 antibody (ready to use;
Medical & Biological Laboratories Co, Ltd, Japan) over-
night at 4°C. The sections were then rinsed and incubated
for 30 minutes with the EnVision peroxidase labeled
polymer conjugated to anti-mouse secondary antibody
(Dako, Carpinteria, CA). After washing the sections, the
reaction product was developed for 5 minutes using 3,3′-
diaminobenzidine (DAB) (Dako, Carpinteria, CA), counter-
stained with hematoxylin and then dehydrated and mounted
in a permanent medium (Consul Mount; Thermo Fisher
Scientific Inc. Waltham, MA, USA). As a positive control
breast cancer sections were used. The sections were viewed
through the Nikon Eclipse 80i (Nikon Instruments Europe
BV , Badhoevedorp, the Netherlands).
The intensity of the staining of both the cytoplasm and
membrane was evaluated. The percentage of stained cells
Table 1 Clinical characteristics of the patient and RCAS1 immuno-
reactivity changes correlating with different parts of the tumor and
various clinico-pathological features (a precise description of these
relationships was presented in the results section of chapters 2 and 3)
Data N (%) Significant RCAS1
immunoreactivity
correlating with different
clinicopathological features
Age 54 (8) No
Grading Yes
G1 1 (1.3%)
G2 25 (33.8%)
G3 48 (64.9%)
FIGO Yes
I 20 (27.0%)
II 10 (13.5%)
III 44 (59.5%)
IV 0
Ca125 before surgery 1823.36 No
Surgery Yes
primary cytoreductive
surgery - optimally
debulked
55 (74.3%)
neoadjuvant chemotherapy
- secondary cytoreductive
surgery
19 (25.7%)
Ascites Yes
0 42 (57.3%)
1 32 (42.7%)
Histology No
Serous adenocarcinoma
(ACS)
31 (41.9%)
Mucinous adenocarcinoma
( ACM)
14 (18.9%)
Endometrioid
adenocarcinoma (ACE)
7 (9.4%)
Male differentiated (MD) 10 (13.5%)
Clear cell carcinoma
(ACC)
4 (5.4%)
Granulosa cell tumors
(GCTs)
8 (10.9%)
Number of chemotherapy
regimens
Yes
1 59 (79.7%)
More than 1 15 (20.3%)
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succeeding approximations we previously described
( J o z w i c k ie ta l .2005). Staining intensity was evaluated
as negative (0) or positive with a grade of 1+ (pale
brown), 2+ (brown) or 3+ (dark brown).
Ki67 immunostaining was performed using consecutive
sections. After deparaffinization, rehydration and antigen
retrieval using PT Link and high pH buffer (Dako,
Carpinteria, CA), the endogenous peroxidase activity was
quenched with a 3% solution of H2O2. Anti-Ki67 primary
monoclonal mouse antibody, clone MIB-1 (Dako), at
dilution 1:100 with EnVision™ FLEX Antibody Diluent
(Dako, Carpinteria, CA) was then applied for 30 minutes.
Next, the subsequent steps of immunostaining were
performed as in RCAS1 labeling. Finally, the percentage
of Ki67-positive cancer cells was evaluated in both the high
and low proliferative areas.
Definitions used methodologically: CI (Cytoplasmatic
Immunoreactivity) – the staining level of cytoplasmatic
structures of the cancer cell; MI (Membrane Immunoreac-
tivity) – the staining level of the cell membrane of the
cancer cell; CP (Central Part) – the older part of the tumor,
without signs of dynamic growth; BP (Border Part) – the
younger part of the tumor, with signs of dynamic growth (e.
g., the presence of small nests of tumor cells, expressions of
stromal reactivity, as inflammatory infiltration and/or types
of stromal modeling pattern).
The categorization of the central and border parts of
the tumors was carried out by means of morphological
assessment. Later, Ki67 immunostaining was performed
in order to evaluate the rate of proliferation in given
areas. We determined the 40%-cutoff point based on the
percentage of Ki67-positive cancer cells (calculated as
follows: mean percentage of Ki67-positive cells for
Fig. 1 Ki67 immunostaining in ovarian cancer. a) The arrow indicates
the area with a high proliferation rate of the border part of the tumor
with a newly invasive ovarian cancer cell group. The arrow heads
indicate areas of the central part of the tumor showing a lower
percentage of the Ki67-positive cells. Scale bar 100 μm. b) The
enlarged area of the central part of the tumor. Scale bar=50 μm. c) The
enlarged area of the newly invasive ovarian cancer cell group. Scale
bar=50 μm
408 Cell Tissue Res (2011) 345:405–414central parts +1SD). The proliferation rate in the areas
of the tumors initially defined as central parts was
s i g n i f i c a n t l yal o w e rw h e nc o m p a r e dt ot h er a t ei nt h e
areas defined as border parts (p<0.0001). In the central
parts of the tumors, 22.75% of the cells were Ki67-
positive while in the border parts 53.70% were Ki67-
positive. The areas showing a higher proliferation rate
than the cutoff point were classified as border parts
while the areas with a proliferation rate below this point
were classified as central parts Fig. 1.
Statistical analysis
The distribution of variables in the study groups of women
checked with the use of the Shapiro-Wilk test showed that
each of the women was different from normal. The
Fig. 2 RCAS1 immunoreactiv-
ity within the ovarian cancer
nest. Scale bars=50 μm. a)
Cytoplasmatic RCAS1 immu-
noreactivity (CI) within the
ovarian cancer cells derived
from the central part of the
tumor (CP) with predominant
minimal staining expression 1+.
b) Cytoplasmatic RCAS1 im-
munoreactivity (CI) within the
ovarian cancer cells derived
from the central part of the
tumor (CP) with predominant
maximal staining expression 2+.
c) Membrane RCAS1 immuno-
reactivity (MI) within the ovar-
ian cancer cells derived from the
central part of the tumor (CP)
with predominant minimal
staining expression 0. d) Mem-
brane RCAS1 immunoreactivity
(MI) within the ovarian cancer
cells derived from the central
part of the tumor (CP) with
predominant maximal staining
expression 1+. e) Cytoplasmatic
RCAS1 immunoreactivity (CI)
within the ovarian cancer cells
derived from the border part of
the tumor (BP) with predomi-
nant minimal staining expres-
sion 2+. f) Cytoplasmatic
RCAS1 immunoreactivity (CI)
within the ovarian cancer cells
derived from the border part of
the tumor (BP) with predomi-
nant maximal staining expres-
sion 3+. g) Membrane RCAS1
immunoreactivity (MI) within
the ovarian cancer cells derived
from the border part of the
tumor (BP) with predominant
minimal staining expression 0.
h) Membrane RCAS1 immuno-
reactivity (MI) within the ovar-
ian cancer cells derived from the
border part of the tumor (BP)
with predominant maximal
staining expression 2+
Cell Tissue Res (2011) 345:405–414 409statistical significance between the groups was determined
by the Kruskal-Wallis test, one-way analysis of variance by
ranks. The Mann-Whitney U test was then used as
applicable. All statistical analyses were carried out with
the Statistica 8.0 software program. A p value<0.05 was
considered indicative of statistical significance.
Results
The characteristic of RCAS1 immunoreactivity
RCAS1 immunoreactivity within the cancer milieu
The levels of RCAS1 immunoreactivity within the cancer
nest were not uniform; the chief differences that we found
were between the levels in the central and border parts of
the tumor. Many apoptotic cells were seen in the central
part of the tumor, which was characterized by high stromal
hyalinization, a small number of fibroblasts, either absence
or presence of single macrophages and little or no
inflammatory reactivity in the tumor microenvironment. In
the border portion of the cancer nest, by contrast, the
proliferation was distinct. For this reason, we decided to
distinguish two parts of the cancer nest, the central part
and the border part and to analyze the RCAS1 immuno-
reactivity levels independently as CP versus BP . Never-
theless, as the ovarian cancer cells were typified by
cytoplasmatic and membrane expression of RCAS1, we
analysed the RCAS1 immunoreactivity in the cytoplasm
independently of the membrane RCAS1 expression as CI
vs MI Fig. 2 Table 2.
RCAS1 immunoreactivity within the ovarian cancer
microenvironment
The level of RCAS1 immunoreactivity was detected within
the cells surrounding the cancer nest, namely, macrophages
(TAM) and carcinoma-associated fibroblasts (CAF). We
observed significant differences in RCAS1 immunoreactiv-
ity levels between the cells infiltrating the cancer nest
microenvironment and those surrounding the central part of
the tumor Fig. 3 Table 3.
RCAS1 immunoreactivity relative
to the clinicopathological features
We found statistically significant differences in RCAS1
immunoreactivity within both macrophages and CAFs and
these differences corresponded to either the presence or
absence of lymph node metastases. The RCAS1 immuno-
reactivity levels were higher in the patients with lymph
node metastases (FIGO IIIc) in comparison to those patients
without lymph node metastases. The cases in which the
differences were statistically significant are presented in
Fig. 4.
In the BP of the tumor, both the RCAS1 cytoplasmatic
immunoreactivity (CI) and RCAS1 immunoreactivity with-
in CAF and macrophages were higher in the cases with
lymph node metastases than in those without lymph node
metatases; the differences, however, were not statistically
significant.
The differences in RCAS1 relative to the grade of the
tumor were observed only in the cytoplasm (CI) of ovarian
cancer cells derived from the central part of the tumor.
RCAS1 immunoreactivity relative to the applied
therapy
We have observed significantly lower RCAS1 cytoplas-
matic immunoreactivity levels in the border parts of the
tumors derived from patients for whom first-line chemo-
therapy was sufficient in comparison to the levels in those
patients who required second-line chemotherapy (p=001).
In addition, we observed statistically significantly higher
levels of RCAS1 immunoreactivity within the macrophages
in the central part of the tumor derived from those patients
on whom neoadjuvant chemotherapy was applied before
cytoreductive surgery in comparison to the levels found in
the macrophages within the tissue samples derived from
patients on whom primary cytoreductive surgery was
performed (p=0.01). Similarly, the level of membrane
RCAS1 immunoreactvity in the central part of the tumor
was significantly higher in those patients who underwent
neoadjuvant chemotherapy but these differences were not
statistically significant (p=0.08). Furthermore, there was a
significantly higher infiltration of RCAS1 positive macro-
phages in the central part of the tumor in patients with
malignant ascites in comparison to those patients without
ascites but this difference was, again, not statistically
significant (p=0.09)
Table 2 RCAS1 immunoreactivity levels (cytoplasmatic and mem-
brane immunoreactivity of RCAS1) within the ovarian cancer milieu
Immunostaining Intensity
0
1 1
1 2
1 3
1
CP-cytoplasm 4 (5.4) 42 (56.8) 27 (36.5) 1 (1.3)
CP-membrane 58 (78.4) 12 (16.2) 4 (5.4) 0 (0.0)
BP-cytoplasm 0 (0.0) 3 (4.1) 41 (55.4) 30 (40.5)
BP-membrane 38 (51.4) 12 (16.2) 16 (21.6) 8 (10.8)
1 – Number of samples (percentage of samples)
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The suppressive profile of the tumor microenvironment
differs according to the tumor zone and may be related to
the development of metastases since a tumor depends on its
microenvironment for its growth. Most likely, the prolifer-
ating zones of the tumor have different microenvironments
and this can be detected by the RCAS1 immunoreactivity
level. The cancer cells from proliferating zones may
develop metastases because the surrounding cells create
the conditions favorable for tumor progression. The tumor
grows within the stroma that is prepared to support this
growth. The presence of an increased number of fibroblasts
demonstrating different types of histological dynamic
mutual arrangements with cancer nests (modeling pattern:
Fig. 1C) along with an increased number of inflammatory
cells (e.g., macrophages) may indicate that a proper
environment for the growth of the tumor has been
Fig. 3 RCAS1 immunoreactiv-
ity within cells infiltrating the
ovarian cancer microenviron-
ment. Scale bars=50 μm. a)
Predominant minimal RCAS1
immunoreactivity within CAF in
the central part of the tumor
(CP) (staining expression 0). b)
Predominant maximal RCAS1
immunoreactivity within CAF in
the central part of the tumor
(CP) (staining expression 1+) c)
Predominant minimal RCAS1
immunoreactivity within CAF in
the border part of the tumor
(BP) (staining expression 1+). d)
Predominant maximal RCAS1
immunoreactivity within CAF in
the border part of the tumor
(BP) (staining expression 2+). e)
Predominant minimal RCAS1
immunoreactivity within the
macrophages infiltrating the
central part of the tumor (CP)
(staining expression 0). Two
regions of the tissue section are
showed. f) Predominant maxi-
mal RCAS1 immunoreactivity
within the macrophages infil-
trating the central part of the
tumor (CP) (staining expression
2+). ). Two regions of the tissue
section are shown. g) Predomi-
nant minimal RCAS1 immuno-
reactivity within the
macrophages in the border part
of the tumor (BP) (staining
expression 2+). h) Predominant
maximal RCAS1 immunoreac-
tivity within the macrophages in
the border part of the tumor
(BP) (staining expression 3+)
Cell Tissue Res (2011) 345:405–414 411established. This is especially true if there is also an
increased expression of RCAS1 (Fig. 1). The stronger
expression of RCAS1 on macrophages is likely connected
with the presence of the M2 macrophage phenotype (Basta
et al. 2011). While M1 macrophages are associated with an
anti-cancer response and are able to increase the activation
of T lymphocytes and NK cell trough secretion of such
cytokines as interleukin-12 or TNF alfa, M2 macrophages
seem to cooperate with cancer cells and constitute the main
part of the suppressive profile that surrounds the tumor. M2
macrophages produce mainly IL-10 and their increased
infiltration is linked with a poorer prognosis for the case in
various types of carcinomas (Nagamatsu and Schust 2010).
RCAS1-positive macrophages were observed in various
types of cancer, including salivary gland carcinoma or brain
tumors (Adamek et al. 2009; Dutsch-Wicherek 2010;
Dutsch-Wicherek et al. 2009). The infiltration of these cells
corresponds to cancer progression (Dutsch-Wicherek et al.
2009). RCAS1-positive macrophages were not detected in
the ovarian cancer microenvironment, although RCAS1
was observed in both the cytoplasm and membrane of
ovarian cancer cells within the cancer nest (Akahira et al.
Table 3 RCAS1 immunoreactivity levels in macrophages and
fibroblasts (CAF) within the ovarian cancer microenvironment
Immunostaining Intensity
0
1 1
1 2
1 3
1
CP-macrophages
2 39 (52.7) 10 (13.5) 15 (20.3) 6 (8.1)
CP-CAF 20 (27.0) 44 (59.5) 10 (13.5) 0 (0.0)
BP-macrophages
3 10 (13.5) 4 (5.4) 31 (41.9) 27 (36.5)
BP-CAF 3 (4.1) 43 (58.1) 24 (32.4) 4 (5.4)
1 – Number of samples (percentage of samples),
2 – In 4 of the
samples there were no macrophages,
3 – In 2 of the samples there
were no macrophages
Fig. 4 Comparison of RCAS1
immunoreactivity according to
the presence of lymph node
metastases: A) without or B)
with. a) Cytoplasmatic RCAS1
immunoreactivity (CI) within
the ovarian cancer cells derived
from the central part of the
tumor (CP) b) Membrane
RCAS1 immunoreactivity (MI)
within the ovarian cancer cells
derived from the central part of
the tumor (CP) c) Membrane
RCAS1 immunoreactivity (MI)
within the ovarian cancer cells
derived from the border part of
the tumor (BP) d) RCAS1 im-
munoreactivity within CAFs
derived from the central part of
the tumor (CP) e) RCAS1 im-
munoreactivity within macro-
phages derived from the central
part of the tumor (CP)
412 Cell Tissue Res (2011) 345:405–4142004; Sonoda et al. 2008; 2009). Moreover, RCAS1
expression in the cancer nest was higher in those patients
who had advanced ovarian cancer (Akahira et al. 2004).
Similarly, Sonoda et al. have observed that patients with
advanced ovarian cancer have higher RCAS1 blood serum
concentration levels (Sonoda et al. 2008). The different
structures of these different microenvironments may be
reflected in their different RCAS1 expression profiles and
changes in RCAS1 immunoreactivity may indicate different
functional potential. Certainly, RCAS1 may support the
development of the suppressive profile of the tumor
microenvironment. Recently, Sonoda et al. found that the
level of RCAS1 correlates inversely with the number of
Vimentin positive cells within the microenvironment of the
ovarian cancer (Sonoda et al. 2009). These cells participate
in connective tissue remodeling, which is in turn directly
linked with overall survival rates. Thus patients with higher
RCAS1 expression (and so lower Vimentin positive cells)
have statistically significantly lower survival rates (Sonoda
et al. 2009). In our study we did not assess survival rates
relative to the level of RCAS1 immunoreactivity but we did
observe higher RCAS1 immunoreactivity levels in patients
who had lymph node metastases. These data may suggest a
relationship between RCAS1 expression and poor progno-
sis. Clearly it cannot be ignored that as RCAS1 increases,
an inhibition of infiltrating cytotoxic T lymphocytes and
NK cells comes into play that allows cancer cells to evade
immune surveillance and the tumor to grow. In our study
we compared various clinical parameters associated with
the outcome of applied therapy, such as the number of
required chemotherapy regiments, the need for neo-
adjuvant chemotherapy application and the primary cytor-
eductive surgery application. Additionally, we observed
alterations in RCAS1 immunoreactivity levels in cases
where there was a response to applied therapy in compar-
ison to those typified by resistance to the applied therapy. In
cases where resistance to therapy was observed, it was
generally linked with a poor prognosis. Therefore, alter-
ation in the microenvironment profile, as measured by the
level of RCAS1 immunoreactivity, may help to predict
resistance to therapy and such resistance indicates a higher
biological potential for the tumor to disseminate.
Conclusion
RCAS1 immunoreactivity is diffuse and not homogeneous
and so the levels of RCAS1 immunoreactivity detected in
the various parts of the tumor differ. RCAS1 staining may
provide information about the intensity of the immune-
suppressive microenvironment profile of ovarian cancer;
the intensity of this suppressive profile may in turn be
related to the clinical outcome of the disease treatment.
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